FDA Probes Risks of HIV, Prostate, Other Drugs
May 4, 2010
The Food and Drug Administration's latest Adverse Event Reporting System update indicates the agency is investigating potential safety issues associated with the HIV drug Kaletra and several other medications. FDA said it is tracking reports of liver toxicity in patients who received Kaletra to prevent HIV infection following exposure to the virus (post-exposure prophylaxis). FDA also is looking into reports of male breast cancer in patients taking the prostate drugs Avodart or Proscar, and in those taking the baldness product Propecia. The quarterly report covers the period October through December 2009. FDA emphasized that "the listing of a drug and a potential safety issue on this Web site does not mean that FDA is suggesting prescribers should not prescribe the drug or that patients taking the drug should stop taking the medication." For more information, click here.
05.03.2010; Lisa Richwine
New Kaletra (Lopinavir/Ritonavir) Tablets and Oral Solution Once Daily Dosing Regimen in Certain Adult Patients
This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.